Literature DB >> 31538770

Nuclease-Assisted Minor Allele Enrichment Using Overlapping Probes-Assisted Amplification-Refractory Mutation System: An Approach for the Improvement of Amplification-Refractory Mutation System-Polymerase Chain Reaction Specificity in Liquid Biopsies.

Athina Markou1, Elena Tzanikou1, Ioannis Ladas2, G Mike Makrigiorgos2, Evi Lianidou1.   

Abstract

Allele-specific polymerase chain reaction (PCR) (amplification-refractory mutation system, ARMS) is one of the most commonly used methods for mutation detection. However, a main limitation of ARMS-PCR is the false positive results obtained due to nonspecific priming that can take place with wild-type (WT) DNA, which often precludes detection of low-level mutations. To improve the analytical specificity of ARMS, we present here a new technology, NAPA: NaME-PrO-assisted ARMS, that overcomes the ARMS deficiency by adding a brief enzymatic step that reduces wild-type alleles just prior to ARMS. We performed this technology for the simultaneous detection of two hot-spot PIK3CA mutations (E545 K and H1047R) in circulating tumor cells (CTCs) and cell free DNA (cfDNA). The developed protocol could simultaneously detect mutation-allelic-frequency of 0.5% for PIK3CA exon 9 (E545 K) and 0.1% for PIK3CA exon 20 (H1047R) with high specificity. We further compared the developed NAPA assay with (a) ddPCR considered as the gold standard and (b) our previous assay based on the combination of allele-specific, asymmetric rapid PCR, and melting analysis. Our data show that the newly developed NAPA assay gives consistent results with both these assays (p = 0.001). The developed assay resolves the false positive signals issue derived through classic ARMS-PCR and provides an ideal combination of speed, accuracy, and versatility and should be easily applicable in routine diagnostic laboratories.

Entities:  

Year:  2019        PMID: 31538770      PMCID: PMC7154944          DOI: 10.1021/acs.analchem.9b03325

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  29 in total

1.  Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing.

Authors:  Jin Li; Lilin Wang; Harvey Mamon; Matthew H Kulke; Ross Berbeco; G Mike Makrigiorgos
Journal:  Nat Med       Date:  2008-04-13       Impact factor: 53.440

2.  Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.

Authors:  Jannik N Andersen; Sriram Sathyanarayanan; Alessandra Di Bacco; An Chi; Theresa Zhang; Albert H Chen; Brian Dolinski; Manfred Kraus; Brian Roberts; William Arthur; Rich A Klinghoffer; Diana Gargano; Lixia Li; Igor Feldman; Bethany Lynch; John Rush; Ronald C Hendrickson; Peter Blume-Jensen; Cloud P Paweletz
Journal:  Sci Transl Med       Date:  2010-08-04       Impact factor: 17.956

3.  DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells.

Authors:  Maria Chimonidou; Areti Strati; Alexandra Tzitzira; Georgia Sotiropoulou; Nikos Malamos; Vasilis Georgoulias; Evi S Lianidou
Journal:  Clin Chem       Date:  2011-06-23       Impact factor: 8.327

4.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  Non-radioactive detection of the most common mutations in the cystic fibrosis transmembrane conductance regulator gene by multiplex allele-specific polymerase chain reaction.

Authors:  P Fortina; R Conant; G Monokian; G Dotti; T Parrella; W Hitchcock; J Kant; T Scanlin; E Rappaport; E Schwartz
Journal:  Hum Genet       Date:  1992-12       Impact factor: 4.132

Review 6.  Liquid biopsies.

Authors:  Evi Lianidou; Klaus Pantel
Journal:  Genes Chromosomes Cancer       Date:  2019-04       Impact factor: 5.006

7.  PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.

Authors:  Magdalena Cizkova; Aurélie Susini; Sophie Vacher; Géraldine Cizeron-Clairac; Catherine Andrieu; Keltouma Driouch; Emmanuelle Fourme; Rosette Lidereau; Ivan Bièche
Journal:  Breast Cancer Res       Date:  2012-02-13       Impact factor: 6.466

8.  Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment.

Authors:  Chen Song; Yibin Liu; Rachel Fontana; Alexander Makrigiorgos; Harvey Mamon; Matthew H Kulke; G Mike Makrigiorgos
Journal:  Nucleic Acids Res       Date:  2016-07-18       Impact factor: 16.971

9.  PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.

Authors:  Eleni Tzanikou; Athina Markou; Eleni Politaki; Anastasios Koutsopoulos; Amanda Psyrri; Dimitris Mavroudis; Vassilis Georgoulias; Evi Lianidou
Journal:  Mol Oncol       Date:  2019-09-30       Impact factor: 6.603

10.  A novel RFLP-ARMS TaqMan PCR-based method for detecting the BRAF V600E mutation in melanoma.

Authors:  Yunqing Zhang; Shoufang Qu; Jinyin Zhao; Ting Yu; Liping Guo; Songchao Yin; Xiaoxu Hu; Weijun Chen; Wei Lai; Jie Huang
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

View more
  6 in total

1.  Nuclease-Assisted, Multiplexed Minor-Allele Enrichment: Application in Liquid Biopsy of Cancer.

Authors:  Fangyan Yu; Ka Wai Leong; G Mike Makrigiorgos
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Pre-PCR Mutation-Enrichment Methods for Liquid Biopsy Applications.

Authors:  Farzaneh Darbeheshti; Fangyan Yu; G Mike Makrigiorgos
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

Review 3.  Liquid Biopsy as a Source of Nucleic Acid Biomarkers in the Diagnosis and Management of Lynch Syndrome.

Authors:  Gergely Buglyó; Jakub Styk; Ondrej Pös; Ádám Csók; Vanda Repiska; Beáta Soltész; Tomas Szemes; Bálint Nagy
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

Review 4.  Molecular Genetic Techniques in Biomarker Analysis Relevant for Drugs Centrally Approved in Europe.

Authors:  Tatjana Huebner; Michael Steffens; Catharina Scholl
Journal:  Mol Diagn Ther       Date:  2021-12-14       Impact factor: 4.074

5.  PIK3CA mutation enrichment and quantitation from blood and tissue.

Authors:  Ieva Keraite; Virginia Alvarez-Garcia; Isaac Garcia-Murillas; Matthew Beaney; Nicholas C Turner; Clare Bartos; Olga Oikonomidou; Maïwenn Kersaudy-Kerhoas; Nicholas R Leslie
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

Review 6.  Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.

Authors:  Hui Zhou; Liyong Zhu; Jun Song; Guohui Wang; Pengzhou Li; Weizheng Li; Ping Luo; Xulong Sun; Jin Wu; Yunze Liu; Shaihong Zhu; Yi Zhang
Journal:  Mol Cancer       Date:  2022-03-25       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.